trial

The Effect of a Weight Management Program During Treatment With Olanzapine

NCTId NCT00169702
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
— · Completed
Enrollment 100 (actual)
Sponsored by Heinrich-Heine University, Duesseldorf
Synthesized from structured facts only — each point cited above.

Design & status

Phase
—
Status
Completed
Enrollment
100 (actual)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
None
Start
2003-06
Primary completion
—
Eligibility
ALL · 18 Years · 65 Years

Interventions & indications

Drugs
weight management program

Sponsors

Heinrich-Heine University, DuesseldorfLead Sponsor
Eli Lilly and CompanyCollaborator
Else Kröner Fresenius FoundationCollaborator
Technical University of MunichCollaborator

Investigators

3
Joachim Cordes, MDPrincipal Investigator
Ansgar Klimke, ProfStudy Director
Hans Hauner, ProfStudy Director

Sites

1 total
Düsseldorf, Germany

Facts & assertions

3 sourced
Enrollment
100
Phase
NA
Status
COMPLETED
relationships
The graph out of here
drug
weight management program
drug
lead_sponsor
Heinrich-Heine University, Duesseldorf
company
collaborator
Eli Lilly and Company
company
Else Kröner Fresenius Foundation
company
indication
Schizophrenia
indication
Schizophrenia
indication
investigator
Joachim Cordes, MD
person
Ansgar Klimke, Prof
person
Hans Hauner, Prof
person